Suzhou Landing Pharmaceuticals

Suzhou Landing Biopharmaceutical is a Chinese biotechnology company specializing in the research, development, and large-scale manufacturing of recombinant protein and peptide therapeutics. Founded by Professor Liu Jianning, the company is best known for the discovery and initial development of Recombinant Human Prourokinase (rhpro-UK), a next-generation thrombolytic agent approved in China for the treatment of acute ST-segment elevation myocardial infarction (STEMI) and commercialized in partnership with Tasly Pharmaceutical. The company's portfolio also includes Recombinant Human Brain Natriuretic Peptide (rhBNP) for heart failure and an innovative oral delivery platform for peptides such as GLP-1 and thymosin. Suzhou Landing operates a 10,000-square-meter GMP-certified production base in the Suzhou Industrial Park and maintains a strategic leadership connection with Junshi Biosciences, with Junshi's Co-CEO Li Cong serving as its Director and General Manager.